Injeq raised 3 million euros in record time

Injeq launched a 3 million euros convertible bond on March 23rd to secure growth. Investors subscribed the loan at a record pace and the loan was fully subscribed a week later.

Injeq first offered an investment opportunity to the existing, approximately 1,200 shareholders, who subscribed the loan at a record pace. A day after the start of the financing round, the accumulated capital had risen to more than one and a half million euros. The public offering began on March 30th, and the loan was fully subscribed on the same day.

Despite the uncertainty caused by the war between Russia and Ukraine in the world economy, shareholders’ confidence in Injeq has remained strong. The impact of the Ukrainian crisis on Injeq’s business is small, at least for the time being. There is nothing related to Russia, Belarus or Ukraine in Injeq’s supply chain, and the company’s products are not sold in these countries.

Now, for the fourth time, the capital raised through Invesdor will be used to finance growth in line with the strategy; marketing, research and development and working capital security. In addition, the revenue stream is sought from the recently started sales. The IPO is still strongly in Injeq’s plans.

Further information

Injeq Oyj
Tommi Rasila, Chairman of the Board
tel. 040 750 8158
tommi.rasila@injeq.com

Injeq Oyj
Timo Hänninen, CEO
tel. 050 518 1830
timo.hanninen@injeq.com

 

Injeq in brief 

Injeq Oyj is a Finnish growth company in innovative medical technology, whose mission is to produce technically intelligent solutions for medically demanding patient injections. Developed at the request of physicians, the IQ-Tip® smart needle facilitates physicians’ work to improve patient safety and treatment effectiveness.

The IQ-Tip® smart needle is a modern way to perform demanding patient injections safely. The first stage is lumbar puncture, a clinical procedure in which the spinal fluid is sampled or a drug is administered into the spinal cavity. The clinical performance and safety of the product at lumbar punctures have been evaluated in three clinical trials in Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, one of the main uses being for the treatment of leukemia children.

Founded in 2010, Injeq operates in Tampere and currently employs 19 people. Injeq is supported by an experienced team of medical experts and extensive scientific research. IQ-Tip® is a registered trademark of Injeq.

Injeq participating SIOP 2022 in Barcelona 28th September -1st October

Injeq is very excited to attend the SIOP Congress to present our amazing IQ-Tip system to doctors, patients and their […]
Read more »

Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this […]
Read more »

German reseller Florian Holderer was dazzled by the smart needle

Ecumed’s CEO Florian Holderer emphasizes the importance of user experience and trust in the marketing of the IQ-Tip®​ smart needle. Florian Holderer […]
Read more »

Changes to the Injeq Plc. Board

The Annual General Meeting held on May 31 2022 made the regular decisions as defined in the by-laws. The new […]
Read more »

Incidence of traumatic lumbar punctures in neonates and infants

The part two of the trilogy has now been published. This article of the three part series examines the incidence […]
Read more »

Injeq whitepaper on lumbar puncture

Our whitepaper takes a closer look at the lumbar puncture, the IQ-Tip® system’s first indication, and presents the results that […]
Read more »